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1. Introduction
Oral cavity cancer is the sixth most prevalent cancer worldwide(1]and comprise about 85% of
all head and neck cancers. Regions with a high incidence of oral cancer ( > 6.9/100,000] are :
North America, Brazil, Europe, South Africa, the Indian Subcontinent, and Australia Areas
with low incidence (< 3.2/100.000] are Central America, Chile, West Africa, Middle East and
China. [2]The higher incidence of oral cancer in high income countries, and increasingly in mid‐
dle-income countries, is thought to be due to tobacco usage, unhealthy diets, alcohol consump‐
tion, inactive lifestyles and infection. The use of tobacco, including smokeless tobacco, and
excessive consumption of alcohol are regarded as the major risk factors for oral cancer. [1]Al‐
though oral cancer originates from different types of tissues that are present in the mouth,
around 85 - 90% are squamous cell carcinomas originating in the oral epithelium.The treatment
of oral cancers is ideally a multidisciplinary approach involving the efforts of surgeons, radia‐
tion oncologists, chemotherapy oncologists, dental practitioners, nutritionists, and rehabilita‐
tion  and  restorative  specialists.  Curative  treatment  modalities  are  usually  surgery  and
radiation, with chemotherapy added to sensitize the malignant cells to radiation, to decrease
the possibility of metastasis, or as curative treatment for those patients who have confirmed dis‐
tant metastasis. The factors that influence the choice of treatment modality are related to the tu‐
mor and the desires of the patient. Primary site, size of the tumor, lymph node involvement and
the presence or absence of distant metastasis are factors which will affect a particular treatment
option. Surgery is the most common treatment for mouth cancer, while oropharyngial cancer is
usually treated with radiation, with or without chemotherapy. Most oncologist consider radio‐
therapy or chemoradiotherapy (CRT) as first-line therapy in oropharynx cancer due to the
equivalent response rates compared with surgery. Salivary gland tumors are commonly treated
with surgery initially. In general, Stage I and Stage II oral cancers may be treated successfully
with either surgery or radiation therapy. Advanced Stage III and Stage IV cancers are typically
treated by surgical resection followed by radiotherapy (RT) or CRT
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2. Radiotherapy
Technological improvements in machines and techniques used for radiation therapy has given
radiotherapy an advantage as the primary modality for treating oral cancer by having less pa‐
tient morbidity and being well tolerated. Radiation therapy for oral cancer will be delivered ei‐
ther by external beam therapy (EBT) or by intensity-modulated radiation therapy (IMRT). EBT
is administered with machines called linear accelerators, which produce high-energy external
radiation beams. This beam or beams of radiation penetrates the tumor delivering tumorcidal
doses. The newer linear accelerators have enabled radiation oncologists to significantly reduce
side effects while improving the capacity to deliver radiation to the cancer with better cure rates.
IMRT is an advanced mode of high-precision radiation therapy that utilizes computer-control‐
led x-ray accelerators to deliver controlled radiation doses to a malignant tumor or specific
areas within the tumor. IMRT allows the precise delivery of high doses of radiation to the tumor
while minimizing damage to adjacent tissues due to the sharp dose falloff gradient between the
gross tumor and the surrounding normal tissue. IMRT can conform to the irregular shape of a
tumor, delivering higher doses directly to the tumor cells with the added potential of also de‐
stroying more radioresistant cells. Numerous data have suggested that IMRT provides locore‐
gional control in 90% of cases and is well tolerated by patients. (3]
2.1. Radiation protocols
A large number of radiotherapy techniques and protocols exist for the treatment of head and
neck cancers. Deciding which technique to use is generally a complex one as it depends on the
size, location and cellular components of the tumor.[4] As mentioned earlier, treatment
modalities can be broadly classified into external beam therapy and intensity-modulated
radiation therapy with few other techniques that have recently gained popularity in treatment
of the head and neck cancer (Table 1). [5]
Table 1. List of commonly utilized radiation techniques. Modified from Clinical Radiation Oncology. 3rd ed. Leonard L.
Gunderson JET, editor. Philadelphia: Saunders; 2012
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External Beam, IMRT and brachytherapy are most commonly used in the head and neck region.
Table 2 presents the list of most commonly occurring head a neck tumors and their general
treatment rational and radiation sensitivity. [6]
Table 2. Treatment of selected tumors. Modified from Ang KK. Advances in the Treatment of Head and Neck Cancer.
In: James D. Cox KKA, editor. Radiation Oncology, Treatment, Technique Rationale. 9th ed. Philadelphia, PA: Mosby,
Elsevier; 2010. p. 161-353
External beam radiotherapy depends on photons, moving packets of energy that deliver radia‐
tion to the tissues. When photons interact with matter, electrons are displaced from their orbits
around the nucleus of the atoms in the irradiated tissue. The atom is left with a positive charge,
and thus becomes an ion/‘free radical’, (hence the term “ionizing radiation”).[7] The process
continues with ionized particles transferring energy and setting more particles in motion. As
the particles travel through the matter, however they continuously loose energy with the maxi‐
mum loss occurring just before they come to rest. (Bragg’s peak)[8] The depth in the tissue that
the Bragg’s peak occurs is dependent on the source of photons, and this is selected by the oncolo‐
gist when determining what X-ray energy to prescribe. Radiation in the external beam therapy
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is generated by linear accelerators. These are complex units that accelerate electrons by provid‐
ing alternating microwave fields and are capable of focusing energy to accommodate target
size. [9] These accelerators are capable of producing a large range of X-ray energy from 50kV to
20MV. For head neck cancers however the most useful range lies in 50-150 kV, the so-called su‐
perficial X-rays. This range is useful for most skin and mucosal cancers. At times when a larger
radiation is required, orthovoltage X-rays can be utilized. This is radiation in the range of
200-300 kV and can penetrate tumors as deep as 3 cm. Intensity modulated radiotherapy (IMRT)
is part of conformal therapy which as an advanced radiotherapy modality that relies on compu‐
terized tomography to calculate and recreate tumor’s exact volume. Intensity modulation refers
to the X-ray’s beams variable strength to deliver exact radiation to the tumor proving maximum
sparing to adjacent tissues. The overall process is outlined in Figure 1.
Figure 1. Intensity modulated radiotherapy treatment planning. Modified from Clinical Radiation Oncology. 3rd ed.
Leonard L. Gunderson JET, editor. Philadelphia: Saunders; 2012
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The treatment planning begins after obtaining an appropriate CT scans of the tumor area as
well any other studies that will facilitate creation of a complete volumetric analysis (including
soft tissue) as well as functional imaging of the tumor area. Three-dimensional model of the
tumor area is then created inside a wide variety of specialized planning software. If needed 4-
D imaging can also be utilized to accommodate motion (i.e. when lungs/ cardiac tissue is
examined). Once the model is completed gross target volume is defined from the CT image
and the radiation oncologist defines the clinical target volume. This is the volume of the tumor
plus any additional area that should be treated.
2.2. Dental preparation of the patient for radiation
The status of the dentition has a significant effect on post-treatment quality of life among
patients with head and neck cancer that will  undergo radiation. A dentition in poor re‐
pair  will  increase  the  risk  of  post-radiation complications,  particularly  dentoalveolar  in‐
fections that  could lead to  osteoradionecrosis.  All  patients  who will  be  treated with RT
for  oral/head and neck cancer  should undergo a  comprehensive dental  evaluation prior
to  treatment.Carious  teeth,  teeth  with  deep  restorations  or  in  poor  periodontal  health,
along with partial  bony impacted third molars should be extracted prior  to RT if  in an
area that is expected to receive a dose of at least 50 Gy. Teeth that are out of the radia‐
tion treatment field, but have a hopeless prognosis or is symptomatic should also be ex‐
tracted.  Extraction  of  healthy  teeth  does  not  appear  to  prevent  the  development  of
osteoradionecrosis.[10]All indicated extractions should be completed prior to RT and pri‐
mary closure over the extraction sites is preferred if possible. An adequate alveoloplasty
should be  performed to  eliminated the  possibility  of  bone edges  ulcerating the  mucosa
as  well  as  to  make  the  mandible/maxilla  ready  for  dentures.  Ideally,  all  extractions
should be completed approximately two weeks before the commencement of RT to per‐
mit proper healing. If the extracted teeth are outside of the treatment areas, however, ra‐
diation may be started sooner. The oral surgeon should attempt to do all the extractions
within  the  portals  of  radiation  at  one  sitting  so  as  not  to  delay  the  cancer  treatment.
Postponing needed extractions of teeth that will  be within the treatment area until  after
radiation is associated with an increased risk of non-healing and osteoradionecrosis.
2.3. Management of radiation associated problems
Radiotherapy  in  the  upper  aerodigestive  tract  can  cause  a  wide  spectrum  of  toxicities.
The most basic toxicities are the impairment in the ability to breathe, communicate, and
maintain  an adequate  oral  intake.  Oral  intake  is  compromised by swallowing problems
(dysphagia and odynophagia),  poor taste (dysgeusia),trismus, xerostomia, and mucositis.
In addition, there may be added dental complications from the effects of radiation dose
to the mandible/maxilla and salivary glands. Acute toxicity is defined as events that oc‐
cur  during  radiation  therapy  or  within  90  days  after  the  commencement  of  treatment
and are largely unavoidable but transient. Late toxicity, can be minimized but is general‐
ly long-lasting and in some instances permanent.
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2.4. Salivary gland damage and xerostomia
Decreased saliva  production  becomes  evident  within  one  to  two weeks  after  the  initia‐
tion  of  RT,  and  permanent  reduction  can  be  noted  with  cumulative  radiation  doses  as
low as 10 to 15 Gy to the parotid gland. [11] Doses greater than 24 to 26 Gy will cause
permanent  damage  to  the  parotid  glands.  This  can  decrease  the  production  of  saliva
from 40-80%.  During  and immediately  after  treatment,  patients  should  be  instructed  to
drink  adequate  fluids  and  to  rinse  and  gargle  with  either  a  dilute  solution  of  25  per‐
cent hydrogen peroxide and 75 percent water or a weak solution of salt  and baking so‐
da  (one-half  teaspoon  of  salt  and  one  teaspoon  of  baking  soda  added  to  one  quart  of
water)  several  times daily.  This regimen can loosen thick,  tenacious oral  secretions,  and
alleviate  pain due to  mild mucositis.[12]  Amifostine  is  a  drug that  can reduce the  inci‐
dence of  xerostomia in patients  undergoing radiotherapy for  head and neck cancer.  Al‐
though it  is  the only pharmacologic agent with established efficacy in the prevention of
xerostomia, its  role in patient management is uncertain and the use of amifostine is not
standard.  For  patients  that  have  lasting  post-radiation  xerostomia,  pilocarpine  may  be
used to  stimulate  saliva  production  from residual  salivary  gland tissue.  However,  pilo‐
carpine  is  not  recommended  to  prevent  xerostomia  in  patients  receiving  RT  for  head
and neck cancer.
2.5. Mucositis
From the second or third weeks onwards, almost all patients undergoing head and neck cancer
RT will experience mucositis. Radiation-induced loss of stem cells in the basal layer interferes
with the replacement of cells in the superficial mucosal layers when they are lost through
normal physiologic sloughing. The subsequent denuding of the epithelium results in muco‐
sitis, which is painful and will interfere with oral intake and nutrition. Mucositis is managed
symptomatically. Good oral hygiene is imperative. Dietary modification will be necessary, and
topical agents for superinfections and pain may be required. The patient should avoid acidic
or spicy foods, sharp foods (eg, chips), caffeine, alcoholic beverages and alcohol-containing
mouthwashes. Secondary bacterial, fungal (oral candidiasis), and viral (herpes) infections
should be treated with appropriate agents. Localized mouth pain can be treated with topical
anesthetics ( example 2 % viscous lidocaine). This may be combined with an antacid suspension
(Mylana,Maalox, Gelusil) and/or diphenhydramine (for local drying effect). Dexamethasone
solution (an anti-inflammatory), tetracycline suspension (antibiotic) or nystatin (antifungal)
may also be added to the mixture.
2.6. Dysgeusia
An abnormal or impaired sense of taste ( the sense of taste may also be affected by im‐
paired olfaction). An altered sense of taste and/or smell may contribute to nutritional dif‐
ficulties  and  weight  loss;  67%  of  patients  treated  by  RT  have  dysgeusia.  There  is  no
successful  treatment  for  this  problem  and  dietary  counseling  should  be  instituted  to
counteract a lack of appetite.
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2.7. Orofacial pain
Long-acting opiates (oxycontin, levorphanol, oxymorphone) should be used as needed during
the treatment period. For patients who cannot swallow oral medication, transdermal fentanyl
may provide good pain relief. Short-acting opiates (morphine, codeine, oxycodone) should be
used for breakthrough pain.
2.8. Trismus
Limited jaw opening during therapy is typically secondary to pain. For that reason, passive
motion devices are generally not used during radiotherapy. By contrast, passive motion
devices (TheraBite, E-Z Flex) can generally be instituted early in the postoperative period.
Adequate pain control will be necessary.
3. Osteoradionecrosis
One of the most serious complications of radiation therapy is postradiation treatment necrosis-
osteoradionecrosis. This is generally a delayed onset disease that usually takes significant
radiation to develop and manifests itself after the irradiated area is subjected to dental surgery,
trauma and ongoing periodontal infection. [13-15] Although osteoradionecrosis is closely
associated with above mentioned factors, spontaneous appearance of the disease is not
unusual with documented incidence in the literature.[16] The incidence of osteoradionecrosis
is variable with 2.6% to 22% for the mandible with significantly lower incidence in the maxilla.
[17, 18] The precise mechanism of injury is still unknown but the progression the disease begins
with a slow change in the matrix of bone after irradiation. The initial changes result from injury
to the remodeling system, i.e. the osteocytes, osteoblasts, and osteoclasts. Osteoblasts tend to
be more radiosensitive than osteoclasts, leading to increase in the initial destruction of bone.
[19, 20]The later changes result from alterations of the vascular system itself; causing funda‐
mental damage to bone architecture. Radiation injury to the fine vasculature of the bone first
leads to hyperemia, followed by endarteritis, thrombosis, and progressive occlusion and
obliteration of the small vessels. This results in a further reduction of the number of cells and
progressive fibrosis within the bone. With time, the marrow exhibits marked acellularity,
hypo- or avascularity, and significant fatty degeneration and fibrosis. The endosteum atro‐
phies with significant loss of active osteoblasts and osteoclasts. The periosteum demonstrates
remodeling with significant overall loss of blood supply.[21] Although in the past osteoradio‐
necrosis was mainly considered an infectious entity[22, 23], it is currently accepted to be a
problem of wound healing with infecting organisms being mostly contaminants. [16] Accord‐
ing to this model the hypoxic, hypovascular, hypocellular tissues have reduced ability to
replace normal cellular and collagen loss, which eventually results in tissue breakdown. The
weakened tissues have reduced ability to heal relevant wounds, since the metabolic demands
exceed the vascular supply. The signs and symptoms of osteoradionecrosis will usually begin
sometime after the radiation therapy. First as an exposed, non-healing area of the bone that
progressively enlarges and becomes painful. The area can show evidence of secondary
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infection with progression to sequestrate formation, cutaneous fistulae and even pathologic
fractures. [18, 24] The diagnosis of osteoradionecrosis is established on a combination of clinical
features and radiological features. Plain dental radiographs show decreased bone density.
Computed tomography scans show bone abnormalities, such as focal lytic areas and cortical
breaks. MRI and as well as bone scans can also be helpful in diagnosis. [25, 26]
Prevention of osteoradionecrosis is centered on patient education and reduction of risks
factors. All carious and non-restorable teeth should be extracted prior to the beginning of the
radiation therapy. Periodontal concerns should be addressed and any teeth with questionable
prognosis should be strongly considered for extractions. If the oral hygiene is controlled and
considered dental surgery is completed 14-21 days prior to beginning of the radiotherapy the
risk of developing osteoradionecrosis becomes insignificant. [27]Extraction of teeth during and
after radiation therapy posses a significant risks for osteoradionecrosis. [28, 29] If extractions
are required in post-radiation therapy then atraumatic surgery is indicated with tension free
primary closure. Antibiotic coverage is also advised with either penicillin or clindamycin. [18,
30]Hyperbarric oxygen therapy should be strongly considered for prevention and treatment
of osteoradionecrosis (see next section).
The mainstay of treatment of osteoradionecrosis remains antibiotic treatment with limited
curettage, debridement and removal ofsequestrae. More extensive surgical therapies are
indicated for refractory lesions [31]. The first step is debridement of all bone that is no longer
vascularized; as this dead bone, if not removed, will continue to promote further bacterial
growth. Further and more invasive surgical techniques include extensive sequestrectomy
combined with marginal or complete resection of affected parts of the mandible (and stabili‐
zation of the continuity defect). Hyperbaric oxygen therapy should be strongly considered as
it has been shown to improve healing. [32]
4. Hyperbaric oxygen
Hyperbaric oxygen is defined as administration of 100% oxygen under pressure that is
significantly higher than the ambient pressure. For patients receiving hyperbaric oxygen it is
possible to administer nearly fifteen times more oxygen. [33] The use of hyperbaric oxygen
(HBO) therapy in osteoradionecrosis is based on the principle that oxygen stimulates collagen
synthesis, matrix deposition, angiogenesis, epithelialization, and the eradication of bacteria.
[34]The immediate effects of breathing high concentrations of oxygen in increased pressure
causes an increase in the tissue’s internal oxygen pressure, leading to vasoconstriction,
enhanced oxygen delivery, edema reduction, phagocytosis activation, and an antiinflamma‐
tory effect. The long-term effects are neovascularization, osteogenesis, and a stimulation of
collagen production by fibroblasts, all promote wound healing. Generally, two types of
chambers exist: monoplace and multiplace. The monoplace chamber is a HBO chamber that
is suited for only one patient with no direct access to the patient while he or she is receiving
the therapy. Multiplace, ICU compatible chambers on the other hand are able to accommodate
multiple patients and even nursing staff. Although the exact mechanism of HBO therapy is
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not understood, what is known is that HBO appears to reverse some of the deleterious effects
of radiation on bone. Several studies that focused on HBO’s effects on osteoblast proliferation
have concluded that HBO has an effect in increasing osteoblasts differentiation into osteogenic
phenotype but not necessarily overall increase in cellularity of the bone.[35]. Use of HBO in
treatment of osteoradionecrosis was discussed as early as 1983, when Marx proposed staging
based on disease progression and response. [16] This was later addressed by Kagan and
Schwartz when they proposed a three-stage system where the disease is classified based on
clinical and radiologic findings and treatment is determined based on the stage, similar to the
approach for malignancies of the head and neck.[36] Figure 2 summarizes treatment proposed
by Marx that is dependent on disease response to HBO therapy.
Figure 2. HBO Treatment protocol based on response to HBO, modified from Marx RE. A new concept in the treat‐
ment of osteoradionecrosis. J Oral Maxillofac Surg. 1983 Jun;41[6]:351-7.
Current treatment protocols vary considerably but they include utilization of panoramic
imaging and CT findings in conjunction with clinical findings to determine if a patient has
early, intermediate, or advanced stage disease. [37]Table 3 summarizes currently accepted
treatment protocols.
Table 3. Summary of Current HBO use in Osteoradionecrosis. Modified from Jacobson AS, Buchbinder D, Hu K, Urken
ML. Paradigm shifts in the management of osteoradionecrosis of the mandible. Oral Oncol. 2010 Nov;46[11]:795-801
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5. Surgery in the post-irradiated patient
Dental extractions or minor oral surgery in patients who have undergone radiation therapy
for cancer in the head and neck carry the risk of one of the most serious and devastating
complications of head and neck radiotherapy, that of osteoradionecrosis (ORN). Elective oral
surgery on irradiated bone should therefore be avoided. The risk of ORN does not decrease
with time. When contemplating exodontia or minor oral surgery in the irradiated patient,
special consideration should be given to issues such as radiotherapy history, surgical assess‐
ment, surgical procedure and the role of antibiotics and hyperbaric oxygen.
The actual field of radiation should be noted as extractions performed outside the area of
radiation do not constitute a risk factor to the development of ORN. Ionizing radiation causes
irreversible cellular and vascular damage resulting in hypoxic, hypocellular and hypovascular
tissue. This fact greatly affects the reparation process and there is a consensus that extractions
in irradiated fields must be executed with as little trauma as possible. Sectioning multi-rooted
teeth, gentle elevation of roots, alveolectomy with careful bone trimming, conservative flaps,
primary closure without tension and removal of few teeth per session minimize postoperative
complications and are associated with lower ORN rates.[38] Prophylactic antibiotics should
be used as adjuvant therapy and the antibiotics continued for 10 – 14 days post-extraction.
There is no consensus about the employment of antibiotics to prevent ORN however, and some
authors have expressed the opinion that an antibiotic as a sole agent is not sufficient to reducing
the risk of ORN. Once dental extractions become unavoidable after radiotherapy, it should be
done with adjuvant therapies – hyperbaric oxygen (HBO) with or without antibiotics- and
rigorous follow-up after the surgical procedures.
The subject of placing dental implants in irradiated bone is not clear. Some papers have shown
that implants can be successfully oseointegrated if HBO is used as an adjuvant therapy. [39]
On the other hand, Franzen et al reported a 95 % (19/20 implants) successful osseointegration
with Brånemark implants placed in irradiated mandibles with stability of the implants after 3
to 6 years of observation. Their oral surgical procedures were carried out without adjunct
hyperbaric oxygen therapy, and their successful results demonstrates that adjunctive measures
are not always necessary in the oral rehabilitation after radiotherapy.
Soft tissue radionecrosis results from damage done to non-osseous tissues by ionizing
radiation during the course of radiotherapy. Once the patient is exposed to the radiation beam,
the soft tissue will begin to manifest ischemic changes. Ischemic tissue may survive without
adequate blood supply for a long period of time, until a traumatic or infectious incident triggers
the events leading to extensive tissue death – soft tissue radionecrosis. Surgeons attempting
maxillofacial surgery in or adjacent to the radiated area will confront numerous complications.
Oozing of blood during the procedure is common and difficult to control. Incisions made
through irradiated tissue may not heal and the risk of infection is increased.
After the first post-irradiation year the most significant problems arising during this peri‐
od  result  from  chronic  deterioration  of  the  microvasculature  with  resulting  hypoperfu‐
sion  and  tissue  hypoxia.  Such  developments  trigger  an  increasing  tissue  fibrosis,
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parenchymal degeneration, and lower resistance to micro-organisms and trauma. The sit‐
uation can be optimized by bringing additional blood supply to the area via a vascular‐
ized flap or  by using HBO.  Treatment  with  hyperbaric  oxygen therapy has  remarkably
changed the  treatment  of  soft  tissue necrosis  disease.  HBO allow tissues  and vessels  to
be hyperoxygenated and promotes healing.
6. Role of chemotherapy in head and neck cancer
The use of chemotherapy in head and neck cancer has evolved greatly over the last three
decades. While it was initially confined to patients with recurrent or metastatic disease, it is
now frequently used as an initial curative component of combined modality therapy. When
combined with radiation therapy,chemotherapy has been shown to enhance the effectiveness
of the radiation making it more active against tumor cells. Chemotherapy by itself, however,
has not changed the recurrence rate of oral squamous cell carcinoma but it has increased the
rates of organ preservation and decreased the rates of distant metastasis when combined with
radiotherapy. Chemotherapeutic agents also have a role in the palliative treatment of squa‐
mous cell cancer of the head and neck. To date, the agents found to be most effective for treating
oral cancer include cisplatinum, carboplatinum, taxanes, 5-fluorouracil, methotrexate, and
ifosphamide. These agents have been used alone or in combination in a variety or regimens.
The agents vary in their single agent response rate and toxicity.
Outside of the head and neck, chemotherapy is used for cancer patients that are not curable
by regional modalities (surgery and/or radiation) and is, at this time, the best adjuvant to local
therapy in a wide range of human malignancies. Although some tumors are treated with a
single medication, chemotherapy regimens most often involve the use of several antineoplastic
drugs (combination therapy).
All chemotherapeutic agents act by interfering with cell division and are most active against
rapidly dividing cells. Malignant tissues are made up of rapidly dividing cells characterized
by rapid synthesis of DNA, and non-dividing cells with slower DNA synthesis. Most of the
drugs used in chemotherapy work by affecting either enzymes or substrates acted upon by
enzyme systems which relate to DNA synthesis or function. For treating cancer the majority
of the agents exploit kinetic differences between normal and malignant cells by acting
preferentially on the cells that are dividing at a faster rate. Consequently, malignant cells will
be destroyed faster than normal cells at the tumor site. However, normal cells that have a high
proliferative capacity rivaling malignant cells (bone marrow, gastrointestinal mucosa, oral
mucosa, skin and hair follicles) will also be severely affected. The side effects of chemothera‐
peutic agents, therefore, include: myelosuppression (leukopenia, thrombocytopenia and
anemia), nausea, vomiting, diarrhea, mucosal ulceration, dermatitides and alopecia.
Oral and maxillofacial surgeons will generally not be treating oral cancer patients with chemo‐
therapy. They may, however, need to manage these patients for oral surgical procedures.
The surgical and anesthetic considerations of patients on cancer chemotherapy will be related
primarily to an awareness of the multiplicity of noxious side effects presented by the various
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drugs. Preoperative evaluation will consist of a thorough history and physical exam, with focus
on the clinical effects of the negative side effects which could increase morbidity and mortality.
Routine laboratory test should include: CBC, serum electrolytes and urinalysis. Depending on
the drug, and other findings a LFT, chest X-ray, EKG and platelet function tests may be
required.
6.1. Chemotherapeutic drugs
Chemotherapy drugs are classified according to how they work. The main types of chemo‐
therapy drugs are described below along with their noxious effects.
6.1.1. Alkylating agents
Alkylating drugs undergo electrophilic chemical reactions that result in the formation of
covalent links (alkylation) with DNA. The 7-nitrogen atom of guanine residues in DNA is
particularly susceptible to formation of a covalent bond which results in a miscoding of DNA
information or opening of the purine ring with damage to the DNA molecule. The alkylating
agent can act on the DNA molecule at any stage of cell division.
Side effects: Bone marrow suppression is the most important- lymphocytopenia is usually
present within 24 hours. Hemolytic anemia, alopecia, nausea and vomiting occurs commonly.
Inhibition of plasma cholinesterase activity can cause prolonged skeletal muscle paralysis after
administration of succinylcholine. Pneumonitis and pulmonary fibrosis may also occur.
Plant alkaloids: Referred to as “Vinca alkaloids” arrest cells in the metaphase of mitosis by
binding to tubulin and thereby inhibiting microtubular function. Useful Vinca alkaloids
derived from the periwinkle plant are Vinblastine and Vincristine. Paclitaxel is an extract of
the bark of the Pacific yew. Despite their structural similarity, there is a not cross tolerance
between them.
Side effects: Myelosuppression (leukopenia, thrombocytopenia and anemia) is the most
common and appears 7 - 10 days after the start of therapy. Other commonly occuring side
effects are: symmetric peripheral sensory-motor neuropathy, ataxia and transient depression.
Autonomic neuropathy with orthostatic hypotension, bowel motility dysfunction, and cranial
nerve involvement {weakness of extraocular muscles and laryngeal nerve paralysis with
hoarseness) are seen in 10% of patients. SIADH occurs with vincristine.
6.1.2. Antimetabolites
Antimetabolites act as fraudulent analogues of vital physiological substrates that inhibit the
synthesis of DNA or its nucleotide building blocks. They include analogues of folic acid
(methotrexate), pyrimidine (cytosine arabinoside) and purine (6-mercaptopurine). These
drugs interact directly with specific enzymes, leading to inhibition of that enzyme and
subsequent synthesis of an aberrant molecule that functions abnormally. These drugs are
immunosuppressants.
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Note: Methotrexate is sometimes used for the treatment of some nonmalignant disorders:
psoriasis and rheumatoid arthritis.
Side effects: Depends on the analogue that is used..
Methotrexate: GI (ulcerative stomatitis and diarrhea) and bone marrow (leukopenia and
thrombocytopenia) side effects are most common. Hemorrhagic enteritis and death from
intestinal perforation are other common side effects. Renal toxicity (10%) and pulmonary
toxicity (8%) may also occur.
Cytosine arabinoside:Myelosuporession (leukopenia, thrombocytopenia and anemia) is the
most common, GI disturbance, stomatitis and hepatic dysfunction also occurs less frequently.
Mercaptopurine: The principal side effect is a gradual development of bone marrow depres‐
sion resulting in thrombocytopenia, granulocytopenia and anemia. Anorexia, nausea and
vomiting are also common. Jaundice associated with bile stasis, and occasionally hepatic
necrosis, occurs in 30% of patients.
6.1.3. Antitumor antibiotics
Antitumor antibiotics are natural products of certain soil fungi. Their effects are produced by
the formation of relatively stable complexes with DNA, thereby inhibiting DNA synthesis,
RNA synthesis, or both. Like antibiotics used for their antimicrobial activities these antitumor
antibiotics all act differently. Some commonly used antibiotics are:
Acinomycin D (Dactinomycin): Binds to DNA in rapidly proliferating cells blocking RNA
polymerase and thus the transcription of DNA.
Bleomycin: Water solubleglycopeptides that differ from one another in their terminal amine
moiety (there are more than 200 congeners). They cause fragmentation of DNA..
6.1.4. Enzymes
L-asparaginase is an enzyme with useful chemotherapeutic effects. It depletes cells of the non-
essential amino acid asparagine. Most human tissue have the capacity to synthesize asparagine
by the action of L-asparagine synthetase. Some tumor cells, particularly those of T-cell lineage,
lack asparagine synthesis capability and require exogenous asparagine to proliferate. As a
result, depletion of circulating pools of asparagine by L-asparaginase results in inhibition of
protein synthesis and ultimately cell death.
Side effects: In contrast to other chemotherapeutic drugs, asparaginase has minmal effects on
bone marrow, oral and GI mucosa,or hair follicle. However, it carries the risk of coagulopathy.
Hepatotoxicity is clinically evident in 10 - 20% of patients (increased P/T) and 50% have
biochemical evidence of liver dysfunction.
6.1.5. Random synthetics
Examples of synthetic chemotherapeutic drugs are: Cisplatin, hydroxyurea, procarbazine, and
mitotane.
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Cisplatin: An inorganic platinum-containing complex (a heavy metal) that enters cells by
diffusion and disrupts the DNA helix. Its action is to cause DNA breaks and cross- link
complimentary DNA strands that prevent replication. Renal toxicity is prominent and can lead
to renal failure. Myelosuppression is also seen, along with ototoxicity (manifested by tinnitus),
nausea, vomiting and peripheral sensory neuropathies.
Hydroxyurea: Acts on the enzyme ribonucleosidediphosphatereductase to interfere with the
synthesis of DNA. Myelosuppression, nausea and vomiting are the major side effects.
Procarbazine: Inhibits DNA synthesis. Myelosuppression, nausea and vomiting are the major
side effects. Sedative effects and depression are prominent. This drug is a weak MAO inhibitor
so tricyclic anidepressant should be used with caution. Synergism occurs with barbiturates,
narcotics, phenothiazines and sedatives.
6.1.6. Hormones
Hormones - corticosteroids, progestin, antiestrogens and antiandrogens - slow the growth of
some cancers that depend on hormones.
Corticosteroids: Possess lympholytic effects and suppress mitosis in lymphocytes. They are
used to treat acute lymphoma in children (not adults) and malignant lymphoma.
Progestins: Used for endometrial carcinoma because it slows the overstimulation of the
endometrium which cause the neoplastic changes.
Estrogens and Androgens: Malignant changes in the breast and prostate often depend on
hormones for their continued growth. For example, prostatic cancer is stimulated by andro‐
gens, so giving estrogen (diethylstilbestrol) will slow the growth of the tumor cells. Estrogens
and androgens are valuable in the treatment of advanced breast cancer. Malignant tissues that
are responsive to estrogens contain receptors for that hormone, whereas malignant tumors
lacking these receptors are unlikely to respond hormonal manipulation. Hypercalcemia is
often associated with androgen or estrogen therapy.
Antiestrogens: Tamoxifen binds to estrogen receptors and inhibits continued growth of
estrogen-dependet tumors. It is used for palliative treatment of advanced cancer of the breast
in postmenopausal females. Side effects are hot flashes, nausea and vomiting.
Antiandrogens: Flutamide is a nonsteroidal antiandrogenic drug used for prostate cancer.
It  prevents  androgen  binding  to  androgen  receptors.  Side  effects  are  skeletal  muscle
weakness, osteoporosis and methemaglobinemia (at levels > 35% pulse oximetry readings
will approach 85%)
7. Oral and maxillofacial surgery considerations
The bone marrow suppression caused by the chemotherapeutic agents will pose the greatest
concerns to the oral and maxillofacial surgeon. Bone marrow suppression is a major side effect
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of nearly all of the widely used agents. It manifests as neutropenia, anemia and thrombocy‐
topenia. The decreases in WBCs and platelets will be the major issues that the surgeon will
need to manage.
Myelosuppression: Caused by nearly all of the chemotherapeutic agents, is reversible and
should be close to normal within 6 – 8 weeks after the drugs have been stopped. The surgeon
should therefore allow about 2 months after chemotherapy for bone marrow to regrow.
Neutropenia and thrombocytopenia will be the major concerns to the surgeon.
Neutropenia: An absolute neutrophil count (ANC) of less than 1500/mm3 The risk for infection
is related to the severity and duration of the neutropenia
Categorization of neutropenia:
1,000 - 1,500 mild
500 – 1000 moderate
< 500 severe
Patients with mild neutropenia do not require prophylactic antibiotic for routine oral sur‐
gery. The authors believe that patients with moderate neutropenia should be given pro‐
phylactic antibiotic for invasive procedures such as tooth extraction, followed by a 7 day
course  of  antimicrobials  to  prevent  secondary  infection.  Severe  neutropenia  cases  must
be  given  prophylactic  antibiotic  for  any  oral  surgical  procedure.  Ciprofloxacin  plus
amoxicillin  are  recommended for  adult  patients  who are  at  low risk  for  complications.
Patients who have higher risk should receive vancomycin. This should also be followed
by a 7 day course of antimicrobials to prevent secondary infection. The antibiotic should
cover the normal oral flora.
Thrombocytopenia: Chemotherapy induced thrombocytopenia typically occurs 6 – 10 days
after administration of the drug. The risk of for excessive bleeding with invasive procedures
occur at counts below 50,000/mm3 Platelet transfusion is the primary method of managing
thrombocytopenia. The usual therapeutic dose for transfusion is one platelet concentrate (1
unit) per 10 kg of body weight. It is expected that one unit will increase the platelet count 5000
– 7000/mm3.Coagulation defects, not caused by thrombocytopenia, may be caused by mech‐
lorethamine, mithramycin and L-asparaginase. Patients who have had these drugs should be
screened by a coagulation profile and abnormalities corrected appropriately. Other noxious
side effects can be managed palliatively.
8. Bisphosphonate related osteonecrosis of the jaw (BRONJ)
In the modern day medicine bisphosphonates are used for management of many conditions
such as osteoporosis, Paget’s disease, breast cancer, prostate cancer and multiple myeloma.
[40]Bisphosphonate related osteonecrosis of the jaw is a pathologic condition resulting in a
non-healing, necrotic sequestrate of bone in patients on past or current bisphosphonate
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therapy. The natural progression of the disease is probably similar with many patients (dental
extraction in a patient with poor oral hygiene who has been on bisphosphonate therapy for a
long period of time). The extraction socket does not heal, or heals but becomes covered with
ulcerated overlying epithelium. Multiple exposed sites of painful bony spicules are present
with occasional purulent exudate. The development of BRONJ appears to depend on the route
and dose of administration of the drug as well as several other risks factors. New clinical
treatments are however, being constantly discovered and it is likely that the uses of bisphosph‐
onates will only increase in the future.
The mode of action of bisphosphonates revolves around the drug’s intricate interaction with
osteoclasts. [41] Once bisphosphonates are circulating in the bloodstream, they are taken up
by osteoclasts, which subsequently undergo physical changes and lose their ruffled borders.
[42] These structural changes in the osteoclasts alone appear to be sufficient to inhibit their
bone resorptive activity. Bisphosphonates also, however, appear to directly cause apoptosis
of osteoclasts and hence decrease overall number of available and viable cells. [43] Lastly
bisphosphonates also inhibit the important osteoclast-osteoblast interaction, disrupting the
important resorption and new deposition pattern. [44] Figure 3 summarizes relative risks of
developing BRONJ.
Figure 3. Risks factors for BRONJ. Modified from Bisphosphonate-related osteonecrosis of the jaws. In: Davies JEA, ed.
Oral Complications of Cancer and Its Management[49]
Route of administration as well  as duration appears to be the most important risks fac‐
tors for developing BRONJ. [45] Most of the literature reports that there are usually trig‐
gering events  (i.e.  dental  extractions,  soft  tissue  trauma)  before  the  disease  makes  itself
visible, others suggest that disease is present long before clinical signs and symptoms be‐
come noticeable.  [46,  47]Regardless  of  the  etiology,  once  the  disease  entity  is  suspected
appropriate staging and management options should be considered. Many clinical associ‐
ations as well as American Association of Oral and Maxillofacial Surgeons have adopted
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concise definitions to facilitate staging and management of the disease. [48] Table 4 sum‐
marizes these diagnostic considerations.
Table 4. BRONJ diagnostic criteria. Modified from BRONJ Diagnosis adopted from American Association of Oral and
Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw. - 2009 update. Aust Endod
J 2009;35[3]:119-130.
The treatment objectives for patients with an established diagnosis of BRONJ are to eliminate
pain, control infection of the soft and hard tissue, and minimize the progression or occurrence
of bone necrosis (see Table 5).[48]
Table 5. BRONJ Management Recommendations. Modified from BRONJ Diagnosis adopted from American
Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw. -
2009 update. Aust Endod J 2009;35[3]:119-130.




Treatment of oral cancer presents a challenge to not only Oral and Maxillofacial surgeons but
also to auxiliary staff, oncologists and certainly patients and their family. Treatment is usually
complex, multidisciplinary and very expensive. The chapter above presents an overview of
types of oral cancers in the mouth and their treatment. The position of an oral and maxillofacial
surgeon remains pivotal; first to perform definitive diagnosis and provide appropriate referral.
This is a rather rapidly changing field in medicine and new advanced treatment modalities
continue to emerge. So it is extremely important to remain current with the most up-to-date
treatment options to better serve the needs of our patients.
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